Floatz logo

Hyaluronidase fihj

Bone Marrow Transplant Rejection

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinsprotein_peptideEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Bone Marrow Transplant Rejection cohort.

Asset / SponsorPhaseRating
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2CCC
TACROLIMUS
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Anti-Thymoglobulin, Rabbit
Masonic Cancer Center, University of Minnesota
Phase 2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2CCC

View all 11 →

Same molecule, other indications

Hyaluronidase fihj is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Transplant IneligibleDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →